Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework
International Journal of Molecular Sciences · 26.11.2025 · 26 (23) · 11443
DOI: 10.3390/ijms262311443 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.11.2025. Verfasst von Soo Im Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cancer Genetics, Columbia University Irving Medical Research Center, 1130 St. Nicholas Ave, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Drug Design, Artificial Intelligence. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, U.S. National Institute of Health, Ministry of Health and Welfare.
Abstract (Originalsprache)
Multi-target drug design represents a paradigm shift in tackling the complexity and heterogeneity of diseases such as cancer. Conventional single-target therapies frequently face limitations due to network redundancy, pathway compensation, and adaptive resistance mechanisms. In contrast, deep generative models, empowered by advanced artificial intelligence algorithms, provide scalable and versatile platforms for the de novo generation and optimization of small molecules with activity across multiple therapeutic targets. This review provides a comprehensive overview of the recent landscape of AI-driven deep generative modeling for multi-target drug discovery, highlighting breakthroughs in model architectures, molecular representations, and goal-directed optimization strategies. We also examine the emergence of self-improving learning systems, closed-loop frameworks that iteratively refine molecular candidates through integrated feedback, as a transformative approach to adaptive drug design. Finally, key challenges, current limitations, and emerging trends are discussed to guide the evolution of next-generation intelligent and autonomous drug discovery pipelines for multi-target therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Cancer Genetics, Columbia University Irving Medical Research Center, 1130 St. Nicholas Ave, New York, NY 10032, USA.
- Qunova Computing Inc., Chrono Building Suite 501, 316 Gajeongro, Daejeon 34130, Republic of Korea.
- Craniofacial Biology and Bioengineering, ADA Forsyth Institute, 100 Chestnut St, Somerville, MA 02143, USA.
- Bioengineering and Nanomedicine Program, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
- School of Materials Science, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi 923-1292, Ishikawa, Japan.
ORCID-Profile: Soo Im Kang, Jae Hong Shin, Hak Soo Choi
Förderung
- NIH HHS
- U.S. National Institute of Health
- Ministry of Health and Welfare
- National Research Foundation of Korea
Zitieren
APA
Kang, S. I., Shin, J. H., Wu, B. M., & Choi, H. S. (2025). Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework. International Journal of Molecular Sciences, 26(23), 11443. https://doi.org/10.3390/ijms262311443
Vancouver
Kang SI, Shin JH, Wu BM, Choi HS. Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework. International Journal of Molecular Sciences. 2025;26(23):11443. doi:10.3390/ijms262311443
BibTeX
@article{Kang2025,
author = {Kang, Soo Im and Shin, Jae Hong and Wu, Benjamin M and Choi, Hak Soo},
title = {Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {23},
pages = {11443},
doi = {10.3390/ijms262311443}
}
EUVIMED